Simplifying Progress

Welcome toSartorius Stedim Biotech
July 2024

Our ambition: Better health for more people

2Mission

At Sartorius Stedim Biotech, we empower engineers tosimplify and accelerate progress in bioprocessing. In thisway, we enable new and better pharmaceuticals to bemanufactured and help keep medications affordable.

VisionWe are a magnet and dynamic platform for pioneers andleading experts in our field. We bring creative minds
together for a common goal: technological breakthroughsthat lead to better health for more people.

Sartorius Stedim Biotech in 2023 numbers~€2,8bn

Sales revenue

28.3%

Profit margin1~90%

Sales with life science customers

10,600+50+
1 Underlying EBITDA margin

3

Employees

Locations worldwide

HQ in Aubagne, France~€470mn
2045

Investments in capacities
Target for climate neutrality

10,600 employees united by strong values

Sustainability

Openness

Enjoyment

Growing profitably andacting responsibly towards
all stakeholders

Driving change
and progressinternally and externally

Working in an energetic
and rewarding
environment

102Nationalities

57%
39%

Women

58%

4Younger than
40 years

Joined since2019The promises of biologics: From established to new concepts
Advantages

What are biopharmaceuticals?

Consist ofcomplex molecules

Obtained from living cells incell culture processes

Administered mainly
intravenously

Target only diseased cells▪

Have fewer side effects▪

Allow first-time or improved treatment ofillnesses, e.g. cancer, multiple sclerosis,
rheumatism

1796

1818

1982

1986

2012 / 20172020

Smallpox
Vaccine

Blood
Transfusion

HumanInsulin

Monoclonal
Antibodies

Cell & GeneTherapymRNA
VaccineEstablished biopharmaceuticals5▪

Next generation

Many biotech medications are highly effective, but very expensive

Rheumatism

Blood cancer

Hemophilia

Monoclonal antibodies

CAR-T cell therapy

Gene therapy~€12,000~€280,000~$3.5mn

Annual cost of treatment in GER

6

Cost per treatment in Europe

Cost per treatment in the USA

The manufacture of biologics is complex

7

Providing technologies to increase productivity in bioprocessing
Our ambition
More efficient bioprocessing

Our solutions
Technologies for all phases of drug manufacturing

Set up safe andflexible processes
Increase resource andmaterial efficiency

Bioreactors & fermenters

Media & reagentsReduce investments
Enhance product yield

8

Chromatography

Filtration

Fluid management

Data analysis

Offering integrated end-to-end manufacturing solutions
Upstream

Production ofthe desireddrug

Cell culture media &preparation

Seed
cultivation

Scale-up

Production

Downstream

Isolation andfilling of thedesired drug
Finalfilling

9

Cryopreservation

Sterilefiltration

Concentration

Virus clearance& filtration

Chromatography

Clarification &centrifugation

Helping customers to reduce their environmental footprint

Single-use
technologies

Biostat® STR Bioreactors

10Processintensification

Linkit® AX

Resolute® BioSMB

Dataanalytics▪

No water-/energyintensive cleaning▪

Less cleanroom space,less energy usage▪

Higher yields

Ambr® 250HT Perfusion

Umetrics SuiteCell and gene therapies: New modalities, new challenges

Next generation biopharmaceuticals
Viral Vectors

mRNA

Stem Cells

ExosomesDNA

New Vaccines

Enabling CGT: High need for innovation

Robustness of production process
Yields, productivity, cost-per-dose

Innovative treatments for patients

6,000+~60

Candidates in development1Regulation under development

Approved therapies worldwide

1 GlobalData, October 2023, CGT = Cell & Gene Therapies

11Time-to-market

Manufacturing close to patients

Creating a technology platform for cell and gene therapy applications

BiologicalIndustries

Cell culturemedia

12CellGenix

Growth factors
and cytokines

XellMedia andsupplements

Albumedix

RecombinantAlbumin

Polyplus

Transfection
reagents andplasmid DNA

Up & downstream solutions

Cell line development,
plasmid design &manufacturing andtesting services

Resilient global setup, well prepared for further growth

Customer proximity

Redundant capacity

Songdo, South Korea
Media, bags, filtration, labs, training

Freiburg, Germany
Cell culture components~12 %Operational excellence

Global resilience

Expected capex
ratio 2024
Göttingen, Germany
Filter production, product development

Expansion of production and R&D capacities; selected current projects

13

Aubagne, France
Clean rooms, product development, labs

Strong financial track record; profitable growth

~16%

3700
3500

High volatility during and post pandemic

Ø Annual growth
2014-2023

3300~€2.8bn

3100
2900
2700

on prior-yearlevel withbandwith of +/lsd % growth

2500
2300
2100
1900
1700

1500
1300
1100
900

~€680m

700

23.5

500
300

27.5

26.2

27.3

28.2

29.3

32.0

35.8

35.0
28.327%-29%

1002014
Sales revenue

2015

2016

2017

2018

2019

EBITDA1 margin in %Sales CAGR for continued operations, in constant currencies; EBITDA margin excluding extraordinary items

14

2020

2021

2022

2023

2024e

69,567,565,563,561,5
59,557,555,553,551,549,547,545,543,541,539,537,535,533,531,529,527,525,523,521,5

Ambitious midterm targets backed by strong market fundamentals

Clear strategy

Expanding market forbiopharmaceuticals incl.
biosimilars

Competitive, integrated
product portfolio

Dynamic market segment ofnovel therapies

Strong, customer-focusedteamHigh need for innovation

1 Thereof around a fifth through acquisitions

15

Ambition to 2028

Growing and aging
world population

Powerful and resilient
production and R&D
infrastructure

Low to mid-teens range
avg. annual sales growth1

above 35%
Underlying EBITDA margin

Broad and ambitious sustainability agenda in implementation

2030 mid-term targets~10%

av. reduction of CO2eq emission
intensity p.a. (Scopes 1-3)

>75%

revenue with products designed
according to circularity principles22045 long-term target

Zero

avoidable1 emissionsin Scopes 1 and 2

Zerooperational waste tolandfill

100%

electricity fromrenewable sources

35

Net-zeroemissions
Decarbonization of the entire
supply chain in collaboration withsuppliers and customers

av. annual Employee
Net Promoter Score

1 Process emissions from membrane manufacturing are currently considered unavoidable based on available technology, 2 Including product and transport packaging

16

Simplifying Progress

Sartorius Stedim Biotech
Zone Industrielle les Paluds
300 Avenue de la Fleuride
13400 AubagneFrance